Navigation Links
BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Date:11/7/2007

Toronto Stock Exchange Symbol: MS

EDMONTON, Nov. 7 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's phase II MINDSET-01 trial of MBP8298 in patients with relapsing-remitting MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the second of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

MINDSET-01 Trial

----------------

The MINDSET-01 phase II, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of MBP8298 in patients with relapsing-remitting MS. The fifteen month trial is fully enrolled with 218 patients at 24 sites in 6 countries. The objectives of the study are to demonstrate safety and efficacy of MBP8298 versus placebo as measured by relapse rate, MRI activity and disease progression.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Amnis Announces the Release of Multiple Upgrades to the ImageStream(R) System
5. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
6. Bioponic Phytoceuticals to Roll Out Multiple Products to 1,000 Major Health Food Stores in the Western United States
7. Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007
8. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014 OHAUS Corporation, ... and mechanical balances and scales, proudly announces its ... won Laboratory Equipment magazine’s 2014 “Readers' Choice” Award ... consecutive year the Explorer was voted the best ... Readers’ Choice Awards celebrates “excellence in product design ...
(Date:7/22/2014)... SHENZHEN, China , July 22, ... (BGI Tech), a subsidiary of BGI, the world,s ... of a new human whole exome sequencing service ... offered service includes in-depth bioinformatics analysis and SNP ... December 31, 2014. Complete Genomics, ...
(Date:7/22/2014)... Quorum Review IRB, the industry leader in central ... called Quick Step™ . The offering went live on ... industry’s need for seamless study start-up with a large volume ... planning 50 or more North American investigator sites, as well ... count of 80 or more. Qualifying studies may also enroll ...
(Date:7/22/2014)... Sunnyvale, CA (PRWEB) July 22, 2014 ... begin on September 9th, 2014 and will comprise of ... and Application’ classes. The TechTrainings is a series of ... professionals, designed to help them reach the next step ... SAS class is taught by Jennifer Kang, Senior ...
Breaking Biology Technology:OHAUS Explorer Voted “Best Balance” in Laboratory Equipment’s 2014 Readers’ Choice Awards 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 3Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 2Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 3Clinovo TechTrainings: Next Session of SAS and CDISC Classes Start 9th September, 2014 2Clinovo TechTrainings: Next Session of SAS and CDISC Classes Start 9th September, 2014 3
... IRVINE, Calif., March 14 Masimo Corporation,(Nasdaq: MASI ), ... pulse oximetry, today announced that it is scheduled,to present at ... The Four Seasons Hotel in Las Vegas, NV on Wednesday, ... and CEO, and Mark P. de,Raad, Executive Vice President and ...
... FRANCISCO, Calif., March 14 ,Renovis, Inc. (Nasdaq: RNVS ... of drugs for major medical needs in the areas ... fourth quarter and year ended December 31, 2007., ... December 31, 2007 was,$1.3 million and $9.8 million, respectively, ...
... Quest Diagnostics,Incorporated (NYSE: DGX ), the ... announced that it is scheduled to speak,at the ... Conference on,Tuesday, March 18, 2008, at the Marriott ... scheduled to begin at,8:45 a.m. Eastern Time., ...
Cached Biology Technology:Masimo to Present at Citi Investment Research 5th Annual Small & Mid-Cap Conference 2Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 2Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 3Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 4Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 5Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 6Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 7Quest Diagnostics to Speak at Cowen and Company 28th Annual Health Care Conference 2
(Date:7/22/2014)... Freezing and thawing might not be good for the ... each fall as they prepare to survive Alaska,s winter ... and thawing outside than a steak does in your ... the spring in better shape than the steak," said ... lead author on a recent paper demonstrating that freeze ...
(Date:7/22/2014)... for Health Policy and Economics have linked tighter ... rates for schizophrenic individuals. , The study comes ... health actually save money, when other costs are ... an extra approval step before tests or treatments ... called prior authorization is intended to encourage ...
(Date:7/22/2014)... light with uncanny precision are key parts of ... manipulate light instead of electricity. But producing these ... with a precise beam of electrons, is often ... Princeton and Columbia universities have proposed a new ... grow these specialized materials, known as photonic crystals, ...
Breaking Biology News(10 mins):Alaska frogs reach record lows in extreme temperature survival 2Alaska frogs reach record lows in extreme temperature survival 3Are state Medicaid policies sentencing people with mental illnesses to prison? 2Technique simplifies the creation of high-tech crystals 2Technique simplifies the creation of high-tech crystals 3
... federal state of Saxony-Anhalt most often suffers from ... by Brandenburg. Hans Hauner of Munich Technical University ... the regional differences in prevalence in general medical ... edition of Deutsches rzteblatt International ( ...
... critical of its life. Having run the gauntlet of air and ... must also evade hungry fish patrolling the beaches in its bid ... cays the risks are high: as many as 30% perish as ... headlong dash through the waves cost the intrepid hatchlings? Curious to ...
... solution to a sticky scientific problem in basic fluid ... even rate, but instead forms what look like fingers ... rivulets "gravity fingers," and the explanation for their formation ... wateror any liquidmeets the soil (or other medium). Knowing ...
Cached Biology News:Cost of hatchling turtles' dash for freedom 2MIT researchers explain mystery of gravity fingers 2
HSV-2 gD (0191)...
...
...
RayBio Human Angiogenesis Antibody Array 2.1 (8 array membranes) with Accessory, detects 23 angiogenic factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: